The invention relates to a molecular complex comprising at least one polylysine conjugate (PLL), comprising a main PLL straight chain and at least one molecule F having an average molecular weight of between 50 daltons and 1000 daltons that is covalently bonded to said main chain, and at least one molecule M that is unstable in solution, the conjugate(s) and the molecule(s) M being bonded by means of a non-covalent bond. The invention also relates to a composition comprising a complex of this kind, to a method for obtaining said composition and use thereof, and to the use of one or more PLL-based conjugates for improving the hydrophilicity, the effectiveness, and the activity of a molecule that is unstable in solution, over a time period that is compatible with the use of said molecule. The invention also relates to a method for identifying a PLL-based conjugate or a combination of a plurality of PLL-based conjugates that makes it possible to improve the hydrophilicity, the effectiveness, and the activity of a molecule that is unstable in solution, and to a kit for implementing said method.

The present disclosure relates to colloids comprising caffeine-tannic acid complexes which slow the release of the caffeine. Also described are methods of preparing the colloids and beverages comprising colloids comprising caffeine-tannic acid complexes.

The present disclosure is drawn to superoxide dismutase (SOD) compositions and methods thereof. A topical composition can comprise a combination of a therapeutically effective amount of superoxide dismutase (SOD) with a stabilizing carrier that is suitable for topical administration. A method of treating a condition in a subject that is responsive to treatment with superoxide dismutase (SOD) can comprise administering a therapeutically effective amount of the topical composition. A method of stabilizing a superoxide dismutase (SOD) composition can comprise combining an amount of SOD with deoxygenated water to form an SOD solution, and minimizing exposure of the SOD solution to reactive oxygen species (ROS).

A pharmaceutical composition including insulin, Docosahexaenoic acid (DHA) and coenzyme Q10 and methods of manufacturing and using the composition are provided.

Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.

In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.

The present disclosure is drawn to superoxide dismutase (SOD) compositions and methods thereof. A topical composition can comprise a combination of a therapeutically effective amount of superoxide dismutase (SOD) with a stabilizing carrier that is suitable for topical administration. A method of treating a condition in a subject that is responsive to treatment with superoxide dismutase (SOD) can comprise administering a therapeutically effective amount of the topical composition. A method of stabilizing a superoxide dismutase (SOD) composition can comprise combining an amount of SOD with deoxygenated water to form an SOD solution, and minimizing exposure of the SOD solution to reactive oxygen species (ROS).

In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.

The present invention is related to a mesoscale colloidal particle including a hydrophobe-rich core surrounded by hydrogen bonded outer shell. The outer shell includes water and at least one hydrotrope wherein the hydrotrope molecules form hydrogen bonds with water molecules. The invention is also related to an aqueous solution including at least one mesoscale colloidal particle as well as methods of making and using such mesoscale colloidal particles and their solutions.

The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to prevent viral infections caused be RNA viruses that have a lipid capcid. An agent for prevention viral infections comprises viral material from RNA viruses that have a lipid capcid and stabilized colloidal selenium at a 1:1 ratio. The viral material from RNA viruses has titres of 6.0-8.0 lg TCD.sub.50/ml. To obtain colloidal selenium having particle sizes from 10 to 15 nm the colloidal selenium is stabilized with polyethylene glycol, and for colloidal selenium having particle sizes from 20 to 40 nm, the colloidal selenium is stabilized with cysteine.